A new ELISA for dermatomyositis autoantibodies: Rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement

Yoshinao Muro, Kazumitsu Sugiura, Masashi Akiyama

研究成果: Review article

20 引用 (Scopus)

抄録

Advances in immunology, biochemistry, and molecular biology have enabled the development of a number of assays for measuring autoantibodies. ELISA has been widely used, because it can deal with relatively large numbers of serum samples more quickly than other immunologic methods, such as immunoblotting and immunoprecipitation. Recombinant autoantigens, which are generally produced in E. coli using the relevant cloned cDNA, are necessary for ELISA. Conventional clinical ELISA tests are limited in their ability to purify proteins free of bacterial contaminants, and the process is labor intensive. We recently developed new ELISA tests that utilize simple in vitro transcription and translation labeling of autoantigens in order to measure dermatomyositis- (DM-) specific autoantibodies, including autoantibodies to Mi-2, MDA5, NXP-2, TIF1-α, and TIF1-γ. This method may allow for the rapid conversion of cDNAs to a chemiluminescent ELISA to detect autoantibodies that are found not only in DM but also in other autoimmune diseases.

元の言語English
記事番号856815
ジャーナルClinical and Developmental Immunology
2013
DOI
出版物ステータスPublished - 01-12-2013

Fingerprint

Dermatomyositis
Autoantibodies
Complementary DNA
Enzyme-Linked Immunosorbent Assay
Autoantigens
Bacterial Physiological Phenomena
Allergy and Immunology
Immunoprecipitation
Immunoblotting
Biochemistry
Autoimmune Diseases
Molecular Biology
To autoantigen
Escherichia coli
Serum
Proteins

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

これを引用

@article{e29f5f7503ba4ca3aa22b08bf85130e2,
title = "A new ELISA for dermatomyositis autoantibodies: Rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement",
abstract = "Advances in immunology, biochemistry, and molecular biology have enabled the development of a number of assays for measuring autoantibodies. ELISA has been widely used, because it can deal with relatively large numbers of serum samples more quickly than other immunologic methods, such as immunoblotting and immunoprecipitation. Recombinant autoantigens, which are generally produced in E. coli using the relevant cloned cDNA, are necessary for ELISA. Conventional clinical ELISA tests are limited in their ability to purify proteins free of bacterial contaminants, and the process is labor intensive. We recently developed new ELISA tests that utilize simple in vitro transcription and translation labeling of autoantigens in order to measure dermatomyositis- (DM-) specific autoantibodies, including autoantibodies to Mi-2, MDA5, NXP-2, TIF1-α, and TIF1-γ. This method may allow for the rapid conversion of cDNAs to a chemiluminescent ELISA to detect autoantibodies that are found not only in DM but also in other autoimmune diseases.",
author = "Yoshinao Muro and Kazumitsu Sugiura and Masashi Akiyama",
year = "2013",
month = "12",
day = "1",
doi = "10.1155/2013/856815",
language = "English",
volume = "2013",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - A new ELISA for dermatomyositis autoantibodies

T2 - Rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement

AU - Muro, Yoshinao

AU - Sugiura, Kazumitsu

AU - Akiyama, Masashi

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Advances in immunology, biochemistry, and molecular biology have enabled the development of a number of assays for measuring autoantibodies. ELISA has been widely used, because it can deal with relatively large numbers of serum samples more quickly than other immunologic methods, such as immunoblotting and immunoprecipitation. Recombinant autoantigens, which are generally produced in E. coli using the relevant cloned cDNA, are necessary for ELISA. Conventional clinical ELISA tests are limited in their ability to purify proteins free of bacterial contaminants, and the process is labor intensive. We recently developed new ELISA tests that utilize simple in vitro transcription and translation labeling of autoantigens in order to measure dermatomyositis- (DM-) specific autoantibodies, including autoantibodies to Mi-2, MDA5, NXP-2, TIF1-α, and TIF1-γ. This method may allow for the rapid conversion of cDNAs to a chemiluminescent ELISA to detect autoantibodies that are found not only in DM but also in other autoimmune diseases.

AB - Advances in immunology, biochemistry, and molecular biology have enabled the development of a number of assays for measuring autoantibodies. ELISA has been widely used, because it can deal with relatively large numbers of serum samples more quickly than other immunologic methods, such as immunoblotting and immunoprecipitation. Recombinant autoantigens, which are generally produced in E. coli using the relevant cloned cDNA, are necessary for ELISA. Conventional clinical ELISA tests are limited in their ability to purify proteins free of bacterial contaminants, and the process is labor intensive. We recently developed new ELISA tests that utilize simple in vitro transcription and translation labeling of autoantigens in order to measure dermatomyositis- (DM-) specific autoantibodies, including autoantibodies to Mi-2, MDA5, NXP-2, TIF1-α, and TIF1-γ. This method may allow for the rapid conversion of cDNAs to a chemiluminescent ELISA to detect autoantibodies that are found not only in DM but also in other autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=84893767879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893767879&partnerID=8YFLogxK

U2 - 10.1155/2013/856815

DO - 10.1155/2013/856815

M3 - Review article

C2 - 24416061

AN - SCOPUS:84893767879

VL - 2013

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

M1 - 856815

ER -